October 2014

New Product - Lozanoc

Lozanoc (itraconazole) is a synthetic triazole antifungal agent. Lozanoc is indicated if external treatment is not effective or not appropriate for the treatment of dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and Pityriasis versicolor. Lozanoc is also indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis and histoplasmosis. Lozanoc is contraindicated with CYP3A4 metabolised substrates that can prolong the QT interval, e.g. sertindole and terfenadine; CYP3A4 metabolised HMG-CoA reductase inhibitors such as simvastatin; potent CYP3A4 inhibitors such as dronedarone; efflux transporter P-glycoprotein substrates, such as dabigatran; triazolam and oral midazolam; ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and ergotamine; and eletriptan. Itraconazole should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life threatening or other serious infections. Itraconazole must not be used during pregnancy for non-life threatening indications. Lozanoc 50 mg capsules (therapeutically equivalent to one 100 mg capsule of conventional itraconazole) are available in blister packs of 15's and 60's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629